Navigation Links
Lymphedema-Pipeline Insights, 2014
Date:9/3/2014

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lymphedema-Pipeline Insights, 2014

http://www.reportlinker.com/p02278640/-Lymphedema-Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Lymphedema-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Lymphedema. This report provides information on the therapeutic development based on the Lymphedema dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Lymphedema
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Lymphedema pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Lymphedema and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Lymphedema
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Lymphedema pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Lymphedema Overview
- Lymphedema Pipeline Therapeutics
- Lymphedema Therapeutics under Development by Companies
- Lymphedema Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Lymphedema Mid Clinical Stage Products (Phase II)

- Comparative Analysis
- Lymphedema Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Lymphedema Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Lymphedema – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Lymphedema – Discontinued Products
- Lymphedema – Dormant Products
- Companies Involved in Therapeutics Development for Lymphedema
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Lymphedema, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Lymphedema Assessment by Monotherapy Products
- Lymphedema Assessment by Combination Products
- Lymphedema Assessment by Route of Administration
- Lymphedema Assessment by Stage and Route of Administration
- Lymphedema Assessment by Molecule Type
- Lymphedema Assessment by Stage and Molecule Type
- Lymphedema Therapeutics – Discontinued Products
- Lymphedema Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Lymphedema, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Lymphedema Assessment by Monotherapy Products
- Lymphedema Assessment by Combination Products
- Lymphedema Assessment by Route of Administration
- Lymphedema Assessment by Stage and Route of Administration
- Lymphedema Assessment by Molecule Type
- Lymphedema Assessment by Stage and Molecule Type

To order this report: Lymphedema-Pipeline Insights, 2014
http://www.reportlinker.com/p02278640/-Lymphedema-Pipeline-Insights-2014.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Leg Ulcers-Pipeline Insights, 2014
2. Lipodystrophy-Pipeline Insights, 2014
3. Liposarcoma -Pipeline Insights, 2014
4. Liver Cirrhosis-Pipeline Insights, 2014
5. Liver Diseases-Pipeline Insights, 2014
6. Liver Fibrosis-Pipeline Insights, 2014
7. Liver Transplantation-Pipeline Insights, 2014
8. Lung Disease-Pipeline Insights, 2014
9. Lung Adenocarcinoma-Pipeline Insights, 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Vestagen Technical Textiles, Inc., a medical ... healthcare and other demanding applications, today announced it has ... replaces Dale Pfost , PhD, who was serving ... also joining Vestagen,s Board of Directors. ® ... barrier technologies that combines fluid repellent, antimicrobial and breathability ...
(Date:2/8/2016)... Ill. , Feb. 8, 2016  Astellas Pharma Inc. ... announced the promotion of James Robinson as president, ... company,s operations in North and South America ... Astellas Pharma US, representing the commercial organization in ... in 2013. Masao Yoshida , who is ...
(Date:2/8/2016)... , Feb. 8, 2016  CTI BioPharma Corp. ... Company received written communication from the U.S. Food and ... FDA has placed a partial clinical hold on the ... Drug ("IND") application for pacritinib. This clinical hold impacts ... the IND and will also affect planned clinical trials. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... , ... According to research by the National Association of ... be certified or obtain continuing education. To increase patient awareness of the lack ... campaign to inform dentists and patients about the possible lack of skills and ...
(Date:2/7/2016)... Texas (PRWEB) , ... February 07, 2016 , ... ... new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and information ... MyDecision™ combines three elements to cut the cost of providing employee healthcare benefits ...
(Date:2/6/2016)... San Rafael, CA (PRWEB) , ... February 06, 2016 , ... ... 2016 Youth Ultimate Coaching Conference (YUCC) . This event brings together top non-profit leaders, ... is “Gender Equity and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... disorder treatment helps to reduce the frequency and level of relapse. ... Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the recovery ...
(Date:2/5/2016)... Ontario (PRWEB) , ... February 05, 2016 , ... ... announced the availability of the company's lighter, sleeker next generation LYNX VR Indoor ... plant. , Improvements in design and manufacturing not only reduce the weight ...
Breaking Medicine News(10 mins):